Resverlogix Receives Two Patents for RVX-208 in China

Calgary, Alberta (ots/PRNewswire) -

Resverlogix Corp. ("Resverlogix" or the "Company") announces that
it has received two China patent approvals covering RVX-208. A
composition of matter patent, China No. 2007 8 0052349.8 titled,
"Compounds for the Prevention and Treatment of Cardiovascular
Disease" was granted until February 2027. A manufacturing patent,
China No. ZL 2009 8 0106586.7 titled, "Methods of Preparing
Quinazolinone Derivatives" was granted until June 2029.

"These two additional patents build upon the growing intellectual
property estate for our core asset, RVX-208. With our Chinese patent
life extending out to June 2029, RVX-208 now has the necessary
protection required for a regional licensing deal in China," stated
Donald McCaffrey, president and CEO of Resverlogix. Mr. McCaffrey
added, "Resverlogix views the ever expanding Chinese pharmaceutical
market as an attractive opportunity which aligns with our regional
licensing strategy. We will continue our discussions with potential
partners at the China Bio Partnering Forum in Shanghai next week." On
April 15th, Resverlogix is one of four selected Canadian companies
who will be presenting at China Bio.

About RVX-208

RVX-208 is a first-in-class, small molecule selective BET
bromodomain inhibitor. BET bromodomain inhibition is an epigenetic
mechanism that can turn disease-causing genes off, returning them to
a healthier state. RVX-208 is the first and only BET inhibitor
selective for BRD4-BD2, producing a nexus of biological effects with
potentially important benefits for patients with diseases such as
cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer's
disease, peripheral artery disease, and chronic kidney disease while
maintaining an excellent safety profile. Resverlogix is planning to
study RVX-208 in a proposed Phase 3 clinical trial in CVD patients
with DM and low HDL.

About Resverlogix

Resverlogix Corp. is developing RVX-208, a first-in-class, small
molecule selective BET bromodomain inhibitor for the potential
treatment of patients with cardiovascular disease, diabetes mellitus,
Alzheimer's disease, peripheral artery disease, and chronic kidney
disease. RVX-208 is the only selective BET bromodomain inhibitor in
clinical trials. Resverlogix's common shares trade on the Toronto
Stock Exchange . For further information please visit
http://www.resverlogix.com. We can be followed on our blog at
http://www.resverlogix.com/blog and via Twitter
https://twitter.com/resverlogix_rvx @Resverlogix_RVX.

This news release may contain certain forward-looking information
as defined under applicable Canadian securities legislation, that are
not based on historical fact, including without limitation statements
containing the words "believes", "anticipates", "plans", "intends",
"will", "should", "expects", "continue", "estimate", "forecasts" and
other similar expressions. In particular, this news release includes
forward looking information relating to research and development
activities and the potential role of RVX-208 in the treatment of
cardiovascular disease, Alzheimer's disease, peripheral artery
disease and chronic kidney disease. Our actual results, events or
developments could be materially different from those expressed or
implied by these forward-looking statements. We can give no assurance
that any of the events or expectations will occur or be realized. By
their nature, forward-looking statements are subject to numerous
assumptions and risk factors including those discussed in our Annual
Information Form and most recent MD&A which are incorporated herein
by reference and are available through SEDAR at http://www.sedar.com.
The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of
the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

For further information, please contact:

Company Contacts:
Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: +1-403-254-9252
Email: don@resverlogix.com

Sarah Zapotichny
Director, Investor Relations & Corporate Communications
Resverlogix Corp.
Phone: +1-403-254-9252
Email: sarah@resverlogix.com

Media:
Tony Russo, Ph.D.
Matt Middleman, M.D.
Russo Partners, LLC
Phone: +1-212-845-4251
Phone: +1-212-845-4272
Email: tony.russo@russopartnersllc.com
Email: matt.middleman@russopartnersllc.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de